iX Biopharma Ltd. (SGX:42C)

Singapore · Delayed Price · Currency is SGD

0.4050

-0.0050 (-1.22%)

Aug 28, 2026, 5:07 PM SGT

1,925% (1Y)

Market Cap	441.12M +2,383.9%
Revenue (ttm)	6.85M -11.8%
Net Income	-7.99M
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,686,100
Open	0.4100
Previous Close	0.4100
Day's Range	0.4000 - 0.4150
52-Week Range	0.0180 - 0.5850
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 10, 2026

About iX Biopharma

iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical company, develops, manufactures, and commercializes therapies for the treatment of acute and breakthrough pain, and other health conditions in Singapore, the United States, China, Australia and internationally. The company operates through Specialty Pharmaceutical and Nutraceutical segments. It offers Wafesil and Silcap for the treatment of male erectile dysfunction; as well as Hypera, a sublingual tetrahydrocannabinol wafer for chronic pain, anxiety, insomnia and other conditions.... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2004

Employees 35

Stock Exchange Singapore Exchange

Ticker Symbol 42C

Full Company Profile

Financial Performance

In fiscal year 2026, iX Biopharma's revenue was 6.85 million, a decrease of -11.77% compared to the previous year's 7.77 million. Losses were -7.99 million, -21.18% less than in 2025.

Financial Statements